oMARIgliptin once A week dpp-4 inhibitor post-marketinG surveillance on safety and Efficacy

oMARIgliptin once A week dpp-4 inhibitor post-marketinG surveillance on safety and Efficacy - MARIAGE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026134

Enrollment

3000

Registered

2017-02-14

Start date

2016-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Omarigliptin naive patients with type 2 diabetes who are eligible for long-term use.

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
[Safety] The incidence of side effects(Primary endpoint) [Efficacy] Overall impression on efficacy HbA1c change from baseline [Other] Compliance status Concomitant therapies	—

Countries

Japan

Contacts

Public ContactYoshie Umeki

MSDK.K. Pharmacovigilance Area

yoshie.umeki@merck.com09050536703

Outcome results